The dynamic interactions between the human host and the trillions of microbiota that make up the microbiome play a critical role in overall health. When this complex system is disrupted or out of balance there is an increased risk of infectious disease and inflammation, as well as developing metabolic and neurological disorders.
To address these imbalances, we are developing compounds designed to modulate specific molecular pathways in both human cells as well as specific microbes at the point of their interaction.
Multiple Modes of Action
Each of our compounds works in one or more of the following ways:
- By down regulating inflammation, via the introduction of compounds which closely mimic certain positive microbial species known to reduce inflammation in the gut.
- By binding with and neutralizing the lectin receptors on the surface of certain pathogenic microbial species to prevent pathogen adhesion. Our compounds act as a decoy, occupying the binding site, leaving the pathogens with no way to infiltrate host cells.
- By aiding proliferation of specific, beneficial bacteria and helping positive bacteria flourish. This is achieved by delivering enzymes which support the growth and proliferation of certain microbial species that support the immune system and/or naturally protect against certain pathogens—either through their metabolic activity or presence in the gut.
Our patent-protected technology combines our experience in microbiology, enzymology (glycosidases) and carbohydrate chemistry to develop small carbohydrate-based molecules that fight disease via a local (GI system) or systemic health effect.